EXOSYSTEMS Inc.

📢 Selected for a 115 million USD ARPA-H Project! 🎉 EXOSYSTEMS has been selected for the Multimodal Sarcopenia Treatment Consortium project! 💪 The ARPA-H Project is an innovative research and development (R&D) initiative benchmarked from the U.S. ARPA-H. It aims to address five key missions: establishing #health security, overcoming unresolved diseases, securing leading-edge #biohealth technologies, improving welfare and care, and innovating essential #medical services, with a total budget of 1.1628 trillion KRW. Among these, the “Multimodal #Sarcopenia Project”, in which EXOSYSTEMS is involved, will receive 15 billion KRW over 4 years and 6 months to develop new treatments and technologies for sarcopenia. The development of sarcopenia treatments under the Korean ARPA-H Project symbolizes a national effort to tackle health issues and create innovative technologies, which is expected to have a positive impact across the entire biohealth industry. Notably, this project includes participation from leading institutions such as GIST, Seoul Asan Medical Center, Inha University Hospital, and Dongguk University Hospital, collaborating to propose a new paradigm in sarcopenia treatment and explore various therapeutic strategies. EXOSYSTEMS delivers AI-powered #digitalhealthcare solutions focused on preventing, diagnosing, and treating sarcopenia, with a mission to enhance muscle health management and improve quality of life through cutting-edge technology. Stay tuned! 🙌 👉 Read more: https://lnkd.in/esGhZgiG

📢2024 BOOM-UP KOREA WEEK Day #2 Come visit EXOSYSTEMS at Boom-Up Korea! 📅 October 22-23, 2024 📌 Hall 1, Exhibition Center 1, KINTEX (Digital Healthcare Showcase Zone) Discover our latest innovations in #digitalhealthcare technology. See you there! EXOSYSTEMS delivers AI-powered digital healthcare solutions focused on preventing, diagnosing, and treating #sarcopenia, with a mission to enhance muscle health management and improve quality of life through cutting-edge technology.✨

📝 Published in the World's Best SCI(E) Journal in Rehabilitation Field ✨ Exosystems' proprietary AI-powered #digital #biomarker technology (MFI) for analyzing neuromuscular function has been published in the world's leading SCI journal in the field of rehabilitation! 🎉 This publication once again validates Exosystems' technological strength and innovation, showcasing our role in leading cutting-edge neuromuscular rehabilitation analysis. Our MFI technology enables precise and innovative muscle function assessment. 🙌🏻 Join us as we shape the future of #rehabilitation technology!

🏆 2024 CES Innovation Award Winner in Digital Health 🏆 ✨ 2024 Digital Health Category ✨ 2020 Tech for a Better World Category ✨ 2020 Health & Wellness Category AI-Powered Digital Biomarker, MFI (Muscle Function Index) Exosystems' MFI is an AI digital biomarker technology that quantitatively analyzes and evaluates neuromuscular function based on measured neuromuscular biosignals. ✅ Quantitative assessment of muscle conditions ✅ Continuous remote monitoring and progress tracking ✅ Fast, affordable, non-invasive measurement of muscle conditions (< 2 minutes)